Blood Purification
Novel Therapies for Hemodialysis Vascular Access Dysfunction: Fact or Fiction!Roy-Chaudhury P. · Kelly B.S. · Melhem M. · Zhang J. · Li J. · Desai P. · Munda R. · Heffelfinger S.C.University of Cincinnati Medical Center, Cincinnati, Ohio, USA
|
|
Blood Purif 2005;23:29–35
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: February 07, 2011
Issue release date: December 2004
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)
For additional information: https://www.karger.com/BPU
Abstract
Hemodialysis vascular access dysfunction is a major cause of morbidity in the hemodialysis population and contributes significantly to the overall cost of end-stage renal disease programs. At a histological level, most hemodialysis vascular access dysfunction (in both native arteriovenous fistulae and PTFE dialysis access grafts) is due to venous stenosis and thrombosis, secondary to venous neointimal hyperplasia. However, despite a wealth of experimental and clinical data on the use of novel therapeutic interventions that target neointimal hyperplasia in the setting of coronary artery disease, there are unfortunately no effective therapeutic interventions for hemodialysis vascular access dysfunction at the present time. This is particularly unfortunate, since neointimal hyperplasia in the setting of hemodialysis vascular access fistulae and grafts could be the ideal clinical model to test novel therapeutic interventions for neointimal hyperplasia.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996;7:523–535.
- McCarley P, Wingard RL, Shyr Y, Pettus W, Hakim RM, Ikizler TA: Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001;60:1164–1172.
- Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989;80:1726–1736.
- Roy-Chaudhury P, Kelly BS, Miller MA, et al: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001;59:2325–2334.
-
DOQI. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000. Am J Kidney Dis 2001;37(suppl 1):S137–S181.
- Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL: Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985;202:235–239.
- Malovrh M: Native arteriovenous fistula: Preoperative evaluation. Am J Kidney Dis 2002;39:1218–1225.
- Pisoni RL, Young EW, Dykstra DM, et al: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 2002;61:305–316.
- Roy-Chaudhury P, Kelly BS, Narayana A, et al: Hemodialysis vascular access dysfunction from basic biology to clinical intervention. Adv Ren Replace Ther 2002;9:74–84.
- Roy-Chaudhury P, Kelly BS, Zhang J, et al: Hemodialysis vascular access dysfunction: From pathophysiology to novel therapies. Blood Purif 2003;21:99–110.
- Keren G: Compensatory enlargement, remodeling, and restenosis. Adv Exp Med Biol 1997;430:187–196.
- Libby P, Tanaka H: The molecular bases of restenosis. Prog Cardiovasc Dis 1997;40:97–106.
- Nakamura Y, Zhao H, Yutani C, Imakita M, Ishibashi-Ueda H: Morphometric and histologic assessment of remodeling associated with restenosis after percutaneous transluminal coronary angioplasty. Cardiology 1998;90:115–121.
- Kwon HM, Sangiorgi G, Ritman EL, et al: Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998;101:1551–1556.
- Shi Y, O’Brien JE, Fard A, Mannion JD, Wang D, Zalewski A: Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996;94:1655–1664.
- Shi Y, O’Brien JE, Jr., Mannion JD, et al: Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997;95:2684–2693.
-
Roy-Chaudhury P ML, Miller M, Reaves A, Armstrong J, Duncan H, Munda R, Kelly B, Heffelfinger S: Adventitial fibroblasts contribute to venous neointimal hyperplasia in PTFE dialysis grafts. J Am Soc Nephrol 2001;12:301A.
External Resources
- Sata M, Saiura A, Kunisato A, et al: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403–409.
- Sata M, Hirata Y, Nagai R: Circulating recipient cells contribute to graft coronary arteriolosclerosis. J Cardiol 2002;39:48–49.
- Yokote K, Take A, Nakaseko C, et al: Bone marrow-derived vascular cells in response to injury. J Atheroscler Thromb 2003;10:205–210.
-
Diao Y GM, Guthrie S, Scott E, Segal MS: Role of circulating progenitor cells in the development of venous intimal hyperplasia. J Am Soc Nephrol 2002;13:58A–59A.
External Resources
- Koc M, Bihorac A, Segal MS: Circulating endothelial cells as potential markers of the state of the endothelium in hemodialysis patients. Am J Kidney Dis 2003;42:704–712.
- Griese DP, Ehsan A, Melo LG, et al: Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: Implications for cell-based vascular therapy. Circulation 2003;108:2710–2715.
- Kong D, Melo LG, Mangi AA, et al: Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004;109:1769–1775.
- Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SB 3rd: Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation 1995;91:1533–1539.
- Wiedermann JG, Marboe C, Amols H, Schwartz A, Weinberger J: Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: Persistent benefit at 6-month follow-up. J Am Coll Cardiol 1995;25:1451–1456.
- Leon MB, Teirstein PS, Moses JW, et al: Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250–256.
- Raizner AE, Oesterle SN, Waksman R, et al: Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000;102:951–958.
- Kelly BS, Narayana A, Heffelfinger SC, et al: External beam radiation attenuates venous neointimal hyperplasia in a pig model of arteriovenous polytetrafluoroethylene (PTFE) graft stenosis. Int J Radiat Oncol Biol Phys 2002;54:263–269.
-
Roy-Chaudhury P, DZ, Duncan H, Foley J, Misra S: Endovascular radiation therapy reduces venous stenosis in PTFE dialysis access grafts. J Am Soc Nephrol 2004, in press.
- Qian HS, Channon K, Neplioueva V, et al: Improved adenoviral vector for vascular gene therapy: Beneficial effects on vascular function and inflammation. Circ Res 2001;88:911–917.
- von der Leyen HE, Gibbons GH, Morishita R, et al: Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137–1141.
- Shears LL 2nd, Kibbe MR, Murdock AD, et al: Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295–306.
- Chang MW, Barr E, Lu MM, Barton K, Leiden JM: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;96:2260–2268.
- Tsui LV, Camrud A, Mondesire J, et al: p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ Res 2001;89:323–328.
- Chang MW, Barr E, Seltzer J, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518–522.
- Hayashi K, Nakamura S, Morishita R, et al: In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000;7:1664–1671.
- Mann MJ, Conte MS: Transcription factor decoys for the prevention of vein bypass graft failure. Am J Cardiovasc Drugs 2003;3:79–85.
- Mann MJ, Whittemore AD, Donaldson MC, et al: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493–1498.
- Stone GW, Ellis SG, Cox DA, et al: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221–231.
- Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773–1780.
- Degertekin M, Serruys PW, Foley DP, et al: Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: Long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610–1613.
- Brauner R, Laks H, Drinkwater DC Jr, et al: Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. J Thorac Cardiovasc Surg 1997;114:53–63.
- Teomim D, Fishbien I, Golomb G, Orloff L, Mayberg M, Domb AJ: Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. J Controlled Release 1999;60:129–142.
- Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ: Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994;93:1243–1249.
- Chaux A, Ruan XM, Fishbein MC, et al: Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998;115:604–614.
- Edelman ER, Nugent MA, Karnovsky MJ: Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ deposition. Proc Natl Acad Sci USA 1993;90:1513–1517.
- Kaul S, Cercek B, Rengstrom J, et al: Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: Role of nuclear factor-kappaB. J Am Coll Cardiol 2000;35:493–501.
- Laham RJ, Sellke FW, Edelman ER, et al: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865–1871.
- Lopez JJ, Edelman ER, Stamler A, Morgan JP, Sellke FW, Simons M: Local perivascular administration of basic fibroblast growth factor: Drug delivery and toxicological evaluation [published erratum appears in Drug Metab Dispos 1996;24:1166]. Drug Metab Dispos 1996;24:922–924.
- Golomb G, Fishbein I, Banai S, et al: Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis 1996;125:171–182.
-
Kelly BMM, Desai P, Kasting G, Zhang J, Li J, Heffelfinger S, Rudich S, Roy-Chaudhury P: Perivascular paclitaxel polymers reduce neointimal hyperplasia and venous stenosis in PTFE arteriovenous grafts: A solution for hemodialysis vascular access ysfunction? J Am Soc Nephrol 2004, in press.
- Dardik A, Liu A, Ballermann BJ: Chronic in vitro shear stress stimulates endothelial cell retention on prosthetic vascular grafts and reduces subsequent in vivo neointimal thickness. J Vasc Surg 1999;29:157–167.
- Bowlin GL, Rittgers SE: Electrostatic endothelial cell transplantation within small-diameter (<6 mm) vascular prostheses: A prototype apparatus and procedure. Cell Transplant 1997;6:631–637.
- Bowlin GL, Rittgers SE: Electrostatic endothelial cell seeding technique for small-diameter (<6 mm) vascular prostheses: Feasibility testing. Cell Transplant 1997;6:623–629.
- Bowlin GL, Rittgers SE, Milsted A, Schmidt SP: In vitro evaluation of electrostatic endothelial cell transplantation onto 4 mm interior diameter expanded polytetrafluoroethylene grafts. J Vasc Surg 1998;27:504–511.
-
Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S: Endothelial progenitor cells: New hope for a broken heart. Circulation 2003;107:3093–3100.
External Resources
- Shirota T, He H, Yasui H, Matsuda T: Human endothelial progenitor cell-seeded hybrid graft: Proliferative and antithrombogenic potentials in vitro and fabrication processing. Tissue Eng 2003;9:127–136.
- Shi Q, Bhattacharya V, Hong-De Wu M, Sauvage LR: Utilizing granulocyte colony-stimulating factor to enhance vascular graft endothelialization from circulating blood cells. Ann Vasc Surg 2002;16:314–320.
- Ohno T, Gordon D, San H, et al: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781–784.
- Brieger D, Topol E: Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997;35:405–413.
- Sousa JE, Costa MA, Abizaid A, et al: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192–195.
Article / Publication Details
First-Page Preview
Published online: February 07, 2011
Issue release date: December 2004
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)
For additional information: https://www.karger.com/BPU
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
